Opthea to Present at Oppenheimer Healthcare Conference

MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer’s 35^th Annual Healthcare Life Sciences Conference and host one-one-one meetings.

Read more at globenewswire.com